fyi - paste from BTC's shareholder newsletter (25/02):"Alchemia:...

fyi - paste from BTC's shareholder newsletter (25/02):

"Alchemia: There is no better example of investor dis-interest than ASX-listed company
Alchemia which is poised to begin generating significant income from the market launch of its
generic heparin product. Despite significant cash reserves (A$12 million) and near-term
revenue forecast by analysts in the order of A$30 million per annum investors value this
business at only A$20 million. In a normal market, Alchemia can reasonably be expected to
be re-rated significantly as income generation becomes a reality."

enough said.

BTC is a significant s'holder in ACL